WBA - Walgreens Boots Alliance, Inc.
After hours:
Chart Events
Price Crosses Moving Average
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 31.19 |
| Open | 31.32 |
| Bid | 31.25 x 2200 |
| Ask | 31.26 x 2200 |
| Day's Range | 31.12 - 31.96 |
| 52 Week Range | 29.48 - 43.93 |
| Volume | |
| Avg. Volume | 7,267,325 |
| Market Cap | 26.962B |
| Beta (5Y Monthly) | 0.71 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.92 (6.33%) |
| Ex-Dividend Date | May 18, 2023 |
| 1y Target Est | N/A |
Fair Value
Related Research
- Fox Business
Chicago Walgreens redesigned with only 2 aisles available for browsing, the rest behind counters: report
A renovated Walgreens store in downtown Chicago now only has two aisles of products available for public browsing while the rest is behind counters.
- Zacks
Walgreens Boots (WBA) Gains From New Alliances Amid Macro Woes
Continued slowdown in generic introduction has been affecting Walgreens Boots' (WBA) margins.
- Zacks
Walgreens Boots Alliance (WBA) Stock Sinks As Market Gains: What You Should Know
Walgreens Boots Alliance (WBA) closed the most recent trading day at $30.32, moving -0.16% from the previous trading session.
- Motley Fool
3 Numbers That Could Make You Think Twice About Walgreens' Dividend
Investors may want to resist the temptation to load up on a dividend that could end up being too good to be true.
- Motley Fool
3 Top Stocks That Just Went on Sale
Shares of Walgreens Boots Alliance (NASDAQ: WBA), Bristol Myers Squibb (NYSE: BMY) and Dominion Energy (NYSE: D) all recently saw 52-week lows. Walgreens, like other pharmacy stocks, has seen earnings decline as foot traffic in stores has fallen. Pharmaceutical company Bristol Myers Squibb is facing increasing generic competition for its former top-selling oncology drug Relivimid, and has seen revenue decline.
- American City Business Journals
Orlando Health buys Walgreens property at its downtown campus. Here's why.
Orlando Health just bought the Walgreens-owned pharmacy property at its downtown-area campus. The nonprofit health system — with $8.1 billion in assets and $5.2 billion in 2022 revenue — bought the 0.5-acre property at 1200 Kuhl Ave. from the Deerfield, Illinois-based pharmacy chain (Nasdaq: WBA) on May 25 for $4.1 million, per Orange County records. The property includes a Walgreens store that is in 3,660 square feet of space.
- InvestorPlace
3 ‘Bargain Stocks’ You Better Avoid at All Costs
Buying stocks and purchasing homes are similar in some ways. For example, homebuyers want to buy a house at a cheap price, but they get suspicious if the price is too low. Investors feel the same way when it comes to buying stocks. That’s because if the price of a home or a stock is too low, it’s natural to wonder if something is horribly wrong with the asset. So, I wanted to point out some of the top risky bargain stocks you’d be better off avoiding. WBA Walgreens Boots Alliance $30.01 MMM 3M $
- Motley Fool
Walgreens Just Got Another Piece of Bad News -- Should You Sell Its Stock?
The problem this time around is another instance of one of the company's bugbears over the last few years: legal settlements pertaining to its filling of opioid drug prescriptions. The latest piece of bad news is that Walgreens agreed on May 17 to a $230 million settlement with the city of San Francisco, which was suing it for lack of sufficient due diligence when it filled prescriptions for opioid medications.
- Zacks
Walgreens Boots Alliance (WBA) Gains But Lags Market: What You Should Know
In the latest trading session, Walgreens Boots Alliance (WBA) closed at $30, marking a +0.1% move from the previous day.
- Investopedia
Dow Jones Today: Index Up on Debt Ceiling Hopes
The Dow Jones Industrial Average rose 1.1%, or 350 points, breaking its weeklong losing streak as negotiators in Washington closed in on a deal to raise the debt ceiling and excitement about artificial intelligence percolated through markets.
- Benzinga
Walgreens' Profit Drive: Employee Cuts Amid Transformation to Consumer Healthcare
Walgreens Boots Alliance, Inc (NASDAQ: WBA) plans to slash 504 employees from its corporate workforce as the drugstore chain transforms into a consumer-centric healthcare company. The downsizing account for 10% of the corporate workforce, and none of the workers will be based at stores, micro fulfillment centers, or call centers, Bloomberg cites the company spokesman Fraser Engerman. Walgreens has been adding primary-care centers to U.S. locations and collaborating with health insurers. It acqui
- Reuters
Pharmacy chain Walgreens Boots Alliance to cut corporate jobs by 10%
Walgreens Boots Alliance Inc said on Friday it would slash its corporate staff by about 10%, as it streamlines operations and focuses on consumer-facing healthcare businesses.
- Motley Fool
Wall Street Expects This Stock to Skyrocket 30%. Is That Realistic?
Shares of the pharmaceutical services leader have fallen close to 17% so far this year while the S&P 500 has risen nearly 8%. Walgreens could be poised to rebound, though. Wall Street expects the stock to skyrocket by 30%.
- Motley Fool
3 Iconic Dow Stocks That Can Safely Double Your Money by 2028
The Dow Jones Industrial Average is composed of 30 time-tested, multinational businesses. Three of them are capable of delivering triple-digit total returns over the next five years.
- Insider Monkey
12 Best Blue Chip Dividend Stocks To Buy
In this article, we will take a look at 12 best blue chip dividend stocks to buy. You can skip our detailed analysis of blue chip companies and dividend stocks, and go directly to read 5 Best Blue Chip Dividend Stocks To Buy. After recording one of its worst performances in 2022, the stock market […]
- Benzinga
No More Bloodshed: Walgreens Makes Peace with Consumers in Theranos Test-Tangle Saga
Walgreens Boots Alliance Inc (NASDAQ: WBA) has reportedly reached a tentative settlement with consumers in Arizona and California who received blood tests from the now-defunct Theranos Inc and alleged that Walgreens Boots was aware of the fraud but turned a blind eye. Theranos was founded in 2003 by Elizabeth Holmes, then 19 years old, and raised over $700 million from venture capitalists and other investors. Theranos' fraud business strategy was built on the premise of performing blood tests wi
- Reuters
Walgreens fights 'staggering' $642 million arbitration award to Humana
National retail pharmacy giant Walgreen Co has asked a U.S. judge to vacate an arbitrator's award of more than $642 million to Humana Health Plan Inc in a drug-pricing dispute, calling the "staggering" sum the result of a "miscarriage of justice." Lawyers for Walgreens made their legal challenge in a filing on Friday in Washington, D.C., federal court, in a clash over prescription drug reimbursement contracts between Walgreens and Humana. Separately, Humana asked the U.S. court to confirm the award.
- Reuters
Walgreens fights 'staggering' $642 mln arbitration award to Humana
National retail pharmacy giant Walgreen Co has asked a U.S. judge to vacate an arbitrator's award of more than $642 million to Humana Health Plan Inc in a drug-pricing dispute, calling the "staggering" sum the result of a "miscarriage of justice." Lawyers for Walgreens made their legal challenge in a filing on Friday in Washington, D.C., federal court, in a clash over prescription drug reimbursement contracts between Walgreens and Humana.
- Motley Fool
Is Walgreens Boots Alliance Stock a Buy Now?
Household name and dividend growth stock Walgreens Boots Alliance (NASDAQ: WBA) hasn't been good to shareholders for some time now. Walgreens is transitioning its business beyond prescriptions and retail stores and is working through a bloated balance sheet from an acquisition spree over the past few years. Here is where Walgreens stands and whether you should consider buying shares or wait it out.
- Motley Fool
Is It Time to Buy the Dow Jones' 3 Worst-Performing Stocks This Year?
The Dow Jones Industrial Average was the best-performing of the three major indexes in 2022, but 2023 hasn't been as kind to the blue chip index. The regional banking crisis has hit the Dow hard, and the rebound in tech stocks has also left it lagging behind the S&P 500 and Nasdaq Composite, which have more exposure to the tech sector. As you can see from the chart below, the Dow is actually down slightly for the year even as the other two indexes have delivered solid gains.
- Investopedia
Dow Jones Today: Intel Pushes Index Higher
The Dow Jones Industrial Average rallied to finish higher by 0.3%, or 115 points, after earlier falling almost 150 points in intraday trading, fueled partly by optimism that U.S. lawmakers will resolve the debt ceiling standoff. The Dow climbed for the second straight day after House Speaker Kevin McCarthy told reporters that the House of Representatives could consider legislation to extend the U.S. debt limit as early as next week, saying negotiations were in a “better place.” The Nasdaq moved up 1.5% to reach a 52-week high, while the S&P 500 also moved higher.
- Benzinga
Florida Governor DeSantis Plans To Declare 2024 Bid Next Week, Walmart & Alibaba Quarterly Earnings, Deutsche Bank To Pay $75M To Settle Jeffrey Epstein Accusers' Suit: Today's Top Stories
Benzinga DeSantis Vs. Trump Official? Florida Governor Reportedly Plans To Declare 2024 Bid Next Week Florida Governor Ron DeSantis is reportedly preparing to announce his candidacy for the 2024 U.S. presidential elections. Sources familiar with the matter have revealed that DeSantis plans to formally announce his Republican nomination bid next week. He intends to submit the required documents to the Federal Election Commission, officially declaring his presidential candidacy around the same tim
- Benzinga
Walgreens Settles Opioid Epidemic Lawsuit with San Francisco for $230M, Says It Does Not Admit Fault
Walgreens Boots Alliance Inc (NASDAQ: WBA) reached a $230 million settlement with San Francisco to settle claims regarding its role in the city's opioid epidemic. Last year, U.S. District Judge Charles Breyer in San Francisco said that Walgreens Boots could be held liable for " substantially contributing" to an opioid epidemic and faulted Walgreens for its "15-year failure" to properly scrutinize opioid prescriptions and flag possible misuse of the drugs. San Francisco had estimated it might cos
- Motley Fool
Can Walgreens Succeed in This Market Where CVS Failed?
When CVS Health (NYSE: CVS) said on May 14 that it would exit its clinical trial services business after just two years in operation, management at Walgreens Boots Alliance (NASDAQ: WBA) was quick to confirm that it would still be moving forward full speed with building out its own service. Now, the smaller pharmacy chain will have the benefit of one less major competitor trying to work with drug developers to build out their clinical trials. Why bother to get into clinical trials in the first place?
- InvestorPlace
3 Dividend Aristocrat Stocks to Buy on Sale Right Now
Dividend payments can be an important source of income for investors. For retirees, dividend payments can help replace employment earnings and supplement pension income. For these reasons, many investors seek out income from stocks that pay high dividends on a consistent basis. The best dividend stocks are known as the “Dividend Aristocrats,” a select group of companies that have raised their dividend payouts for at least 25 consecutive years. Dividend Aristocrats are a rare breed. There are onl
